CTTH (CTT Pharmaceutical Holdings) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

CTT Pharmaceutical Holdings Quality Rank Related Terms

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.